参考文献

[1] Ferlay J,Soerjomataram I,Ervik M.GLOBOCAN 2012 v1.0,Cancer Incidence and Mortality Worldwide:IARC Cancer Base No.11.Lyon,France:International Agency for Research on Cancer.

[2] Shen Q,Fan J,Yang XR,et al.Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma:a large-scale,multicentre study.Lancet Oncol,2012,13(8):817-826.

[3] Aravalli RN,Steer CJ,Cressman EN.Molecular mechanisms of hepatocellular carcinoma.Hepatology,2008,48(6):2047-2063.

[4] Warburg O, Wind F, Negelein E.The Metabolism of Tumors in the Body.J Gen Physiol,1927,8(6):519-530.

[5] Ward PS,Thompson CB.Metabolic reprogramming:a cancer hallmark even warburg did not anticipate.Cancer Cell,2012,21(3):297-308.

[6] Zheng L,Yang W,Wu F,et al.Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.Clin Cancer Res,2013,19(19):5372-5380.

[7] Chen HP,Shieh JJ,Chang CC,et al.Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner:population-based and in vitro studies.Gut,2013,62(4):606-615.

[8] Driessens G,Beck B,Caauwe A,et al.Defining the mode of tumour growth by clonal analysis.Nature, 2012, 7412(488):527-530.

[9] Jordan CT,Guzman ML,Noble M.Cancer stem cells.N Engl J Med,2006,355(12):1253-1261.

[10] Schepers AG,Snippert HJ,Stange DE,et al.Lineage tracing reveals Lgr5+stem cell activity in mouse intestinal adenomas.Science,2012,6095(337):730-735.

[11] Ma S,Chan KW,Hu L,et al.Identification and characterization of tumorigenic liver cancer stem/progenitor cells.Gastroenterology,2007,132(7):2542-2556.

[12] Sell S,Leffert HL.Liver cancer stem cells.J Clin Oncol,2008,26(17):2800-2805.

[13] Yamashita T,Wang XW.Cancer stem cells in the development of liver cancer.J Clin Invest,2013,123(5):1911-1918.

[14] Yang ZF,Ho DW,Ng MN,et al.Significance of CD90+cancer stem cells in human liver cancer.Cancer Cell,2008,13(2):153-166.

[15] Lee TK,Castilho A,Cheung VC,et al.CD24(+)liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.Cell Stem Cell,2011,9(1):50-63.

[16] Yang W,Wang C,Lin Y,et al.OV6(+)tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma.J Hepatol,2012,57(3):613-620.

[17] Zhao W,Wang L,Han H,et al.1B50-1,a mAb raised against recurrent tumor cells,targets liver tumor-initiating cells by binding to the calcium channel alpha2delta1 subunit.Cancer Cell,2013,23(4):541-556.

[18] Wagers AJ.The stem cell niche in regenerative medicine.Cell Stem Cell,2012,10(4):362-369.

[19] Bruix J,Sherman M.Management of hepatocellular carcinoma:an update.Hepatology,2011,53(3):1020-1022.

[20] Avila MA,Berasain C,Sangro B,et al.New therapies for hepatocellular carcinoma.Oncogene,2006,27(25):3866-3884.

[21] Villanueva A,Toffanin S,Llovet JM.Linking molecular classification of hepatocellular carcinoma and personalized medicine:preliminary steps.Curr Opin Oncol,2008,20(4):444-453.

[22] Ji J,Shi J,Budhu A,et al.MicroRNA expression,survival,and response to interferon in liver cancer.N Engl J Med,2009,361(15):1437-1447.

[23] Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med,2008,359(4):378-390.

[24] Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomised,double-blind, placebo-controlled trial.Lancet Oncol,2009,10(1):25-34.

[25] Llovet JM,Pena CE,Lathia CD,et al.Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clin Cancer Res,2012,18(8):2290-2300.